Lab
Ambry Genetics Corporation
Ambry Genetics Corporation was paid $47.42M by Medicaid between Jan 2018 and Nov 2024, across 48 billing codes. Its largest line is 81162, — 44% of everything it billed.
33Billing provider infoAMBRY GENETICS CORPORATION
ALISO VIEJO, CA 92656
ALISO VIEJO, CA 92656
33aNPI1861568784assigned 11/24/2006
33bProvider typeClinical Medical Laboratory
28Total paid$47.42M
24GClaims151,542
24DCodes billed48
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#21 of 561
Median peer was paid$222K
This provider vs. median214×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,839 | $5.66M | |
| 2019 | 19,913 | $4.40M | |
| 2020 | 25,800 | $5.43M | |
| 2021 | 33,428 | $7.12M | |
| 2022 | 18,354 | $7.24M | |
| 2023 | 16,163 | $8.37M | |
| 2024incomplete | 18,045 | $9.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81162 | 44% | 32,682 | 30,680 | $20.94M | |
| 81479 | Unlisted molecular pathology procedure | 18% | 10,016 | 7,580 | $8.35M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.2% | 28,064 | 21,915 | $1.98M |
| 81416 | 4.2% | 594 | 516 | $1.97M | |
| 81415 | 3.6% | 1,328 | 1,187 | $1.72M | |
| 81211 | 3.4% | 2,281 | 2,023 | $1.59M | |
| 81292 | 3.0% | 6,998 | 6,529 | $1.40M | |
| 81317 | 2.5% | 6,909 | 6,448 | $1.21M | |
| 81298 | 2.3% | 6,983 | 6,509 | $1.09M | |
| 81408 | 1.6% | 2,011 | 1,734 | $755K | |
| 81406 | 1.5% | 4,257 | 3,365 | $700K | |
| 81295 | 1.4% | 6,979 | 6,503 | $658K |
36 more codes
| 81229 | 1.4% | 1,773 | $656K | |
| 81201 | 1.4% | 2,414 | $647K | |
| 81432 | 1.0% | 2,800 | $479K | |
| 81405 | <1% | 2,764 | $452K | |
| 81321 | <1% | 2,421 | $423K | |
| 81407 | <1% | 1,347 | $336K | |
| 81404 | <1% | 2,692 | $248K | |
| 81433 | <1% | 2,467 | $240K | |
| 81213 | <1% | 1,788 | $238K | |
| 81403 | <1% | 3,572 | $238K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 803 | $118K |
| 81294 | <1% | 2,152 | $100K | |
| 81319 | <1% | 2,119 | $97K | |
| 81300 | <1% | 2,132 | $95K | |
| 81297 | <1% | 2,142 | $95K | |
| 81223 | <1% | 614 | $88K | |
| 81460 | <1% | 374 | $81K | |
| 81435 | <1% | 384 | $67K | |
| 81436 | <1% | 312 | $47K | |
| 81302 | <1% | 523 | $44K | |
| 81307 | <1% | 293 | $41K | |
| 81439 | <1% | 262 | $40K | |
| 81419 | <1% | 49 | $35K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,865 | $24K |
| 81243 | <1% | 737 | $19K | |
| 81413 | <1% | 113 | $18K | |
| 81411 | <1% | 41 | $17K | |
| 81323 | <1% | 487 | $17K | |
| 81414 | <1% | 105 | $14K | |
| 81304 | <1% | 370 | $13K | |
| 81410 | <1% | 52 | $11K | |
| 81329 | <1% | 273 | $9K | |
| 81442 | <1% | 14 | $3K | |
| 81401 | <1% | 138 | $3K | |
| 0134U | <1% | 23 | $2K | |
| 81203 | <1% | 25 | $1K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARTINSON, MICHAEL (CFO)